High amounts of HMGB1 cytoplasmic (mRNA) expression (with ensuing cellular release) were detected more often in basal-like or triple-negative breast cancers, than the hormonal and HER2 counterparts, with considerable pertinence to adverse consequences in patients with cancer [82]. Here, ERBB2 is linked to cancer.